In a filing, Xenon Pharmaceuticals Inc revealed its Director GAROFALO ELIZABETH A. unloaded Company’s shares for reported $95583.0 on Mar 08 ’24. In the deal valued at $45.69 per share,2,092 shares were sold. As a result of this transaction, GAROFALO ELIZABETH A. now holds 0 shares worth roughly $0.0.
Then, GANNON STEVEN sold 13,000 shares, generating $601,615 in total proceeds. Upon selling the shares at $46.28, the Director now owns 2,000 shares.
Before that, ROBIN SHERRINGTON sold 7,137 shares. Xenon Pharmaceuticals Inc shares valued at $330,290 were divested by the EVP, Strategy & Innovation at a price of $46.28 per share. As a result of the transaction, ROBIN SHERRINGTON now holds 8,398 shares, worth roughly $0.35 million.
Citigroup initiated its Xenon Pharmaceuticals Inc [XENE] rating to a Buy in a research note published on January 04, 2024; the price target was $62. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in early December with a ‘”an Outperform”‘ rating. Cantor Fitzgerald started covering the stock on April 25, 2023. It rated XENE as “an Overweight”.
Price Performance Review of XENE
On Friday, Xenon Pharmaceuticals Inc [NASDAQ:XENE] saw its stock fall -3.89% to $41.30. Over the last five days, the stock has lost -2.25%. Xenon Pharmaceuticals Inc shares have fallen nearly -10.33% since the year began. Nevertheless, the stocks have risen 17.03% over the past one year. While a 52-week high of $50.99 was reached on 03/01/24, a 52-week low of $27.99 was recorded on 04/12/24. SMA at 50 days reached $45.50, while 200 days put it at $39.64. A total of 0.58 million shares were traded, compared to the trading of 0.19 million shares in the previous session.
Levels Of Support And Resistance For XENE Stock
The 24-hour chart illustrates a support level at 40.34, which if violated will result in even more drops to 39.37. On the upside, there is a resistance level at 42.47. A further resistance level may holdings at 43.63. The Relative Strength Index (RSI) on the 14-day chart is 37.23, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.13, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.64%. Stochastics %K at 38.20% indicates the stock is a holding.
The most recent change occurred on December 14, 2022 when Goldman began covering the stock and recommended ‘”a Buy”‘ rating along with a $60 price target.
